DGIdb - IRINOTECAN Drug Record

IRINOTECAN chembl:CHEMBL481 ApprovedAntineoplasticImmunotherapy

Alternate Names:

CAMPTOSAR
IRINOTECAN
IRINOTECAN MYLAN
BIOTECAN
IRINOTECAN LACTONE
HSDB 7607
IRINOPHORE C
CAMPTOTHECIN-11
(+)-IRINOTECAN
chemidplus:97682-44-5
rxcui:51499
pubchem.compound:60838
chembl:CHEMBL481
drugbank:00762

Drug Info:

Year of Approval	1996
Drug Class	antineoplastic agents
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antineoplastic agent

(9 More Sources)

Publications:

Freyer G et al., 2011, Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study., Anticancer Res
Massacesi et al., 2006, Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy., Cancer
Martinez-Balibrea et al., 2010, UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy., Br. J. Cancer
Kostopoulos et al., 2009, Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy., BMC Cancer
Yoshikawa et al., 2004, Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells., Int. J. Cancer
Nakagawa et al., 2006, Molecular modeling of new camptothecin analogues to circumvent ABCG2-mediated drug resistance in cancer., Cancer Lett.
Ramesh et al., 2010, Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives., Biomed. Chromatogr.
Ishikawa et al., 2006, Transport mechanism-based drug molecular design: novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cells., Curr. Pharm. Des.
Yang et al., 2005, Novel agents that potentially inhibit irinotecan-induced diarrhea., Curr. Med. Chem.
Yoshikawa et al., 2004, Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid., J. Exp. Ther. Oncol.
Chabot, 1997, Clinical pharmacokinetics of irinotecan., Clin Pharmacokinet
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Wang MJ et al., 2014, Design, synthesis, mechanisms of action, and toxicity of novel 20(s)-sulfonylamidine derivatives of camptothecin as potent antitumor agents., J Med Chem
de Oliveira Figueiredo P et al., 2014, Further constituents of Galianthe thalictroides (Rubiaceae) and inhibition of DNA topoisomerases I and IIα by its cytotoxic β-carboline alkaloids., Bioorg Med Chem Lett
Chaniyara R et al., 2013, Novel antitumor indolizino[6,7-b]indoles with multiple modes of action: DNA cross-linking and topoisomerase I and II inhibition., J Med Chem
Hoskins JM et al., 2008, Irinotecan pharmacogenetics: influence of pharmacodynamic genes., Clin Cancer Res
Takahashi H et al., 2014, Application of a combination of a knowledge-based algorithm and 2-stage screening to hypothesis-free genomic data on irinotecan-treated patients for identification of a candidate single nucleotide polymorphism related to an adverse effect., PLoS One
LoRusso et al., 2016, Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors., Clin. Cancer Res.
Chen S et al., 2015, ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients., Pharmacogenet Genomics
De Roock et al., 2010, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis., Lancet Oncol.
Ahmed et al., 2013, Epigenetic and genetic features of 24 colon cancer cell lines., Oncogenesis
Smakman et al., 2006, KRAS(D13) Promotes apoptosis of human colorectal tumor cells by ReovirusT3D and oxaliplatin but not by tumor necrosis factor-related apoptosis-inducing ligand., Cancer Res.
Mallon et al., 2011, Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor., Clin. Cancer Res.
Gerdes et al., 2013, GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab., Clin. Cancer Res.
Hechtman et al., 2015, AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants., Mol. Cancer Res.
Maitra et al., 2014, Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan., Oncotarget
Peeters et al., 2015, Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer., Clin. Cancer Res.
Canon et al., 2015, The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents., Mol. Cancer Ther.
Hochster et al., 2015, Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer., Cancer Chemother. Pharmacol.
French D et al., 2011, KRAS mutation detection in colorectal cancer by a commercially available gene chip array compares well with Sanger sequencing., Clin Chim Acta
Kinehara et al., 2015, Favorable response to trastuzumab plus irinotecan combination therapy in two patients with HER2-positive relapsed small-cell lung cancer., Lung Cancer
Li M et al., 2018, ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia., Pharmacogenomics J
Boisdron-Celle M et al., 2017, A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification., Semin Oncol
Yao et al., 2017, Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., Nature
Hsu HC et al., 2016, Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients., Oncotarget
Yang et al., 2012, Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer., Cancer Res.
Silkin SV et al., 2016, Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan., J Gastrointest Cancer
Souglakos J et al., 2009, Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer., Br J Cancer
Hong et al., 2016, Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation., Cancer Discov
Loupakis et al., 2009, KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer., Br. J. Cancer
Koschmann et al., 2016, ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma., Sci Transl Med
Ruzzo A et al., 2008, Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy., Pharmacogenomics J
Li J et al., 2016, A novel genetic score model of UGT1A1 and TGFB pathway as predictor of severe irinotecan-related diarrhea in metastatic colorectal cancer patients., J Cancer Res Clin Oncol
Subhash et al., 2016, ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis., Mol. Cancer Ther.
Guemei et al., 2001, Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: correlations with SN-38 pharmacokinetics during a prolonged infusion of irinotecan., Cancer Chemother. Pharmacol.
Sebio A et al., 2014, Intergenic polymorphisms in the amphiregulin gene region as biomarkers in metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan., Pharmacogenomics J
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Wang L et al., 2015, Association between Polymorphisms in Vascular Endothelial Growth Factor Gene and Response to Chemotherapies in Colorectal Cancer: A Meta-Analysis., PLoS One
Hansen TF et al., 2011, The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer., Pharmacogenomics J
Fujita K et al., 2008, Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI)., Biol Pharm Bull
Han JY et al., 2009, Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer., Lung Cancer
De Mattia E et al., 2013, Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment., Pharmacogenet Genomics
Ogino et al., 2007, CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma., Virchows Arch.
Banerjee et al., 1998, Role of E2F-1 in chemosensitivity., Cancer Res.
Han JY et al., 2013, A genome-wide association study for irinotecan-related severe toxicities in patients with advanced non-small-cell lung cancer., Pharmacogenomics J
Volz NB et al., 2015, Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer., Pharmacogenomics J
Bowen et al., 2007, Irinotecan changes gene expression in the small intestine of the rat with breast cancer., Cancer Chemother. Pharmacol.
Lévesque E et al., 2013, Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens., J Pharmacol Exp Ther
Han JY et al., 2006, Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin., J Clin Oncol
Gagné JF et al., 2002, Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38)., Mol Pharmacol
De Mattia E et al., 2016, Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine., Pharmacogenomics
Mbatchi LC et al., 2016, Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients., Clin Pharmacokinet
Al-Ahmadie H et al., 2014 Sep, Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy., Cancer Discov
Chen S et al., 2015, A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patients., Pharmacogenomics J
Budai B et al., 2012, Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI+bevacizumab., Pharmacogenet Genomics
Cui et al., 2012, Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity., Clin. Cancer Res.
Satoh et al., 2015, Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer., Gastric Cancer
Aguilera et al., 2015, Nuclear DICKKOPF-1 as a biomarker of chemoresistance and poor clinical outcome in colorectal cancer., Oncotarget
Han JY et al., 2014, A genome-wide association study of survival in small-cell lung cancer patients treated with irinotecan plus cisplatin chemotherapy., Pharmacogenomics J
Han JY et al., 2010, Association of SUMO1 and UBC9 genotypes with tumor response in non-small-cell lung cancer treated with irinotecan-based chemotherapy., Pharmacogenomics J

IRINOTECAN TOP1MT

Interaction Score: 4.28

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name CPX-1

Novel drug target Established target

Trial Name PEP-02

PMIDs:
15170677 16309825 19852077 16454746 15975002 15255290 9342501 11752352 17016423 17139284

Sources:
TdgClinicalTrial
IRINOTECAN SEMA3C

Interaction Score: 2.33

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22664479

Sources:
PharmGKB
IRINOTECAN RAD50

Interaction Score: 2.33

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24934408

Sources:
CIViC
IRINOTECAN C8ORF34

Interaction Score: 2.33

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22664479

Sources:
PharmGKB
IRINOTECAN UBE2I

Interaction Score: 1.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19859084

Sources:
PharmGKB
IRINOTECAN DCBLD1

Interaction Score: 1.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23478653

Sources:
PharmGKB
IRINOTECAN ISG15

Interaction Score: 1.17

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial
IRINOTECAN TGFBR2

Interaction Score: 1.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27160286

Sources:
PharmGKB
IRINOTECAN RUNX3

Interaction Score: 1.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17372756

Sources:
NCI
IRINOTECAN ABCG1

Interaction Score: 0.78

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26352872

Sources:
PharmGKB
IRINOTECAN KLC1

Interaction Score: 0.78

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17549067

Sources:
PharmGKB
IRINOTECAN XRCC3

Interaction Score: 0.78

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17549067

Sources:
PharmGKB
IRINOTECAN CES2

Interaction Score: 0.58

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
IRINOTECAN UGT1A

Interaction Score: 0.58

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25778466

Sources:
PharmGKB
IRINOTECAN RGS5

Interaction Score: 0.58

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25069475

Sources:
PharmGKB
IRINOTECAN SHMT1

Interaction Score: 0.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22044939

Sources:
PharmGKB
IRINOTECAN AREG

Interaction Score: 0.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23959273

Sources:
PharmGKB
IRINOTECAN DKK1

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25788273

Sources:
CIViC
IRINOTECAN UGT1A9

Interaction Score: 0.34

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23386248 18221820 16636344 12181437

Sources:
PharmGKB
IRINOTECAN ABCC5

Interaction Score: 0.33

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26352872

Sources:
PharmGKB
IRINOTECAN KCNQ5

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25127363

Sources:
PharmGKB
IRINOTECAN TOP1

Interaction Score: 0.27

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name CPX-1

Novel drug target Established target

Trial Name irinotecan hydrochloride injection,Camptosar

PMIDs:
19775480 15170677 16309825 19852077 16454746 15975002 15255290 9342501 11752352 25003995 24507920 23360284 18347181

Sources:
DTC ClearityFoundationBiomarkers TdgClinicalTrial ClearityFoundationClinicalTrial TEND CIViC MyCancerGenomeClinicalTrial PharmGKB TTD
IRINOTECAN ATRX

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

Approval Status Preclinical

PMIDs:
26936505

Sources:
JAX-CKB
IRINOTECAN DPYD

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28395759

Sources:
PharmGKB
IRINOTECAN BCHE

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11345644

Sources:
NCI PharmGKB
IRINOTECAN SMAD4

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type pancreatic cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
22753594

Sources:
JAX-CKB
IRINOTECAN TYMS

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21273624 16456808 20628391

Sources:
CIViC PharmGKB
IRINOTECAN E2F1

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9766655

Sources:
NCI
IRINOTECAN BRAF

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Cetuximab + Irinotecan

Indication/Tumor Type colorectal cancer

Response Type resistant

PMIDs:
28783719 26989027 22180495 26687137 19603024 27729313 25714871 19603018

Sources:
JAX-CKB CIViC
IRINOTECAN KRAS

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Irinotecan + Selumetinib

Indication/Tumor Type colorectal cancer

Response Type predicted – sensitive

PMIDs:
20619739 24042735 16707468 21325073 23209031 25714871 24798549 26341920 25567130 25322874 21575616

Sources:
JAX-CKB CIViC
IRINOTECAN SLC19A1

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
IRINOTECAN CES1

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
IRINOTECAN BRCA2

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Irinotecan + Veliparib

Indication/Tumor Type ovarian cancer

Response Type predicted – sensitive

PMIDs:
26842236

Sources:
JAX-CKB
IRINOTECAN MTHFR

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16456808

Sources:
NCI
IRINOTECAN VEGFA

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25955730 20125120

Sources:
PharmGKB
IRINOTECAN TYMSOS

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
IRINOTECAN MAPK10

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16799812

Sources:
NCI
IRINOTECAN ABCC4

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23478653

Sources:
PharmGKB
IRINOTECAN ABCC2

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18981587 18221820

Sources:
PharmGKB
IRINOTECAN TGFB1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27160286

Sources:
PharmGKB
IRINOTECAN ABCG2

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24018773 18221820

Sources:
PharmGKB
IRINOTECAN PIN1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
IRINOTECAN ATM

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

Approval Status Preclinical - Cell line xenograft

Response Type sensitive

combination therapy Irinotecan + Veliparib

PMIDs:
27638859

Sources:
JAX-CKB
IRINOTECAN PIK3CA

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Cetuximab + Irinotecan

Indication/Tumor Type colorectal cancer

Response Type sensitive

PMIDs:
24042735 16707468 21325073 25714871

Sources:
JAX-CKB
IRINOTECAN AKT1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Cetuximab + Irinotecan

Indication/Tumor Type colorectal cancer

Response Type resistant

PMIDs:
25714871

Sources:
JAX-CKB
IRINOTECAN NR1I2

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27561454 27116457

Sources:
PharmGKB
IRINOTECAN UGT1A1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
FDA
IRINOTECAN BRCA1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Irinotecan + Veliparib

Indication/Tumor Type ovarian cancer

Response Type predicted – sensitive

PMIDs:
26842236

Sources:
JAX-CKB
IRINOTECAN EGFR

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Irinotecan + Nimotuzumab

Indication/Tumor Type stomach cancer

Response Type predicted – sensitive

PMIDs:
25185971 23209031

Sources:
JAX-CKB
IRINOTECAN ERBB2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25601188

Sources:
CIViC
IRINOTECAN ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27845419

Sources:
PharmGKB
IRINOTECAN TP53

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell line xenograft

Response Type sensitive

PMIDs:
25567130

Sources:
JAX-CKB
IRINOTECAN VDR

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB

TdgClinicalTrial: IRINOTECAN
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small Molecule

FDA Approval approved

Publications:
TEND: IRINOTECAN
- Version: 01-August-2011
Alternate Names:

Drug Info:

Drug Class antineoplastic agents

Year of Approval 1996

Publications:

NCI: IRINOTECAN

Version: 14-September-2017

Alternate Names:

C1381 NCI drug code

Drug Info:

Publications:

Banerjee et al., 1998, Role of E2F-1 in chemosensitivity., Cancer Res.

Bowen et al., 2007, Irinotecan changes gene expression in the small intestine of the rat with breast cancer., Cancer Chemother. Pharmacol.

Massacesi et al., 2006, Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy., Cancer

DTC: IRINOTECAN

Version: 02-September-2020

Alternate Names:

CHEMBL481 ChEMBL Drug ID

Drug Info:

Publications:

Wang MJ et al., 2014, Design, synthesis, mechanisms of action, and toxicity of novel 20(s)-sulfonylamidine derivatives of camptothecin as potent antitumor agents., J Med Chem

Chaniyara R et al., 2013, Novel antitumor indolizino[6,7-b]indoles with multiple modes of action: DNA cross-linking and topoisomerase I and II inhibition., J Med Chem

de Oliveira Figueiredo P et al., 2014, Further constituents of Galianthe thalictroides (Rubiaceae) and inhibition of DNA topoisomerases I and IIα by its cytotoxic β-carboline alkaloids., Bioorg Med Chem Lett

JAX-CKB: Irinotecan

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Canon et al., 2015, The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents., Mol. Cancer Ther.

Cui et al., 2012, Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity., Clin. Cancer Res.

Yao et al., 2017, Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., Nature

PharmGKB: irinotecan

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Takahashi H et al., 2014, Application of a combination of a knowledge-based algorithm and 2-stage screening to hypothesis-free genomic data on irinotecan-treated patients for identification of a candidate single nucleotide polymorphism related to an adverse effect., PLoS One

Fujita K et al., 2008, Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI)., Biol Pharm Bull

Han JY et al., 2009, Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer., Lung Cancer

CIViC: IRINOTECAN

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Yao et al., 2017, Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., Nature

Loupakis et al., 2009, KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer., Br. J. Cancer

Silkin SV et al., 2016, Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan., J Gastrointest Cancer

TTD: Irinotecan
- Version: 2020.06.01
Alternate Names:

D07HOB TTD Drug ID

Drug Info:

Publications:
ClearityFoundationBiomarkers: IRINOTECAN
- Version: 26-July-2013
Alternate Names:

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL481
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
MyCancerGenomeClinicalTrial: IRINOTECAN
- Version: 30-February-2014
Alternate Names:

Drug Info:

Publications:
ClearityFoundationClinicalTrial: IRINOTECAN
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:
FDA: Irinotecan
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

Trial Name	CPX-1
Novel drug target	Established target
Trial Name	PEP-02

Indication/Tumor Type	glioblastoma multiforme
Response Type	sensitive
Approval Status	Preclinical

Indication/Tumor Type	pancreatic cancer
Response Type	sensitive
Approval Status	Preclinical

combination therapy	Cetuximab + Irinotecan
Indication/Tumor Type	colorectal cancer
Response Type	resistant

combination therapy	Irinotecan + Selumetinib
Indication/Tumor Type	colorectal cancer
Response Type	predicted – sensitive

combination therapy	Irinotecan + Veliparib
Indication/Tumor Type	ovarian cancer
Response Type	predicted – sensitive

Approval Status	Preclinical - Cell line xenograft
Response Type	sensitive
combination therapy	Irinotecan + Veliparib

combination therapy	Irinotecan + Nimotuzumab
Indication/Tumor Type	stomach cancer
Response Type	predicted – sensitive

Evidence Type	Actionable
Approval Status	Preclinical - Cell line xenograft
Response Type	sensitive

IRINOTECAN Drug Record

IRINOTECAN chembl:CHEMBL481 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name CPX-1 Novel drug target Established target Trial Name PEP-02

PMIDs: 15170677 16309825 19852077 16454746 15975002 15255290 9342501 11752352 17016423 17139284

Sources: TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22664479

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24934408

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22664479

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19859084

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23478653

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenomeClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27160286

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17372756

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26352872

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17549067

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17549067

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25778466

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25069475

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22044939

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23959273

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25788273

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23386248 18221820 16636344 12181437

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name CPX-1

Novel drug target Established target

Trial Name PEP-02

PMIDs:
15170677 16309825 19852077 16454746 15975002 15255290 9342501 11752352 17016423 17139284

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
22664479

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24934408

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
22664479

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
19859084

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23478653

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
27160286

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17372756

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
26352872

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17549067

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17549067

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25778466

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25069475

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22044939

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23959273

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25788273

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
23386248 18221820 16636344 12181437

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26352872

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25127363

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name CPX-1

Novel drug target Established target

Trial Name irinotecan hydrochloride injection,Camptosar

PMIDs:
19775480 15170677 16309825 19852077 16454746 15975002 15255290 9342501 11752352 25003995 24507920 23360284 18347181

Sources:
DTC ClearityFoundationBiomarkers TdgClinicalTrial ClearityFoundationClinicalTrial TEND CIViC MyCancerGenomeClinicalTrial PharmGKB TTD

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

Approval Status Preclinical

PMIDs:
26936505

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
28395759

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
11345644

Sources:
NCI PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type pancreatic cancer

Response Type sensitive

Approval Status Preclinical